Mycophenolate mofetil for liver‐transplanted patients
References
Additional references
Bennett WM, DeMattos A, Meyer MM, Takeshi A, Barry MB. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney International 1996;50:1089‐110.
Bennett WM. The nephrotoxicity of new and old immunosuppressive drugs . Renal Failure 1998 ; 20 ( 5 ):687‐90.
Chardot C, Nicoluzzi JE, Janssen M, Sokal E, Lerut J, Otte JB, et al. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation 2001;71(2):224‐9.
DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341‐50.
DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed) 1997;315(7109):629‐34.
Ettenger R, Bartosh S, Choi L, Zhu W, Niederberger W, Campestrini J, et al. Pharmacokinetics of enteric‐coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatric Transplantation 2005;9:780‐7.
Eurotransplant. Yearly Statistics 2006. http://www.eurotransplant.nl/files/annual_report/AR2006_def.pdf.
Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005;79(11):1575‐80.
Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis . Transplantation 1998 ; 66 ( 1 ):59‐66.
Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, et al. Four‐year follow‐up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clinical Transplantation 2004;18(4):463‐72.
Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor‐sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clinical Transplantation 2008;22(1):1‐15.
Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als‐Nielsen B, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))2008; Vol. Issue 3. Art.No.:LIVER.
Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. End‐stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin‐based immunotherapy . Transplantation 2001 ; 72 ( 12 ):1934‐9.
Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database of Systematic Reviews 2006, Issue 4. [Art. No.: CD005161. DOI: 10.1002/14651858.CD005161.pub2.]
Herrero JI, Quiroga J, Sangro B, Girala M, Gómez‐Manero N, Pardo F, et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transplantation and Surgery 1999;5(5):414‐20.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9.
Klupp J, Pfitzmann R, Langrehr JM, Neuhaus P. Indications of mycophenolate mofetil in liver transplantation. Transplantation 2005;80(1 Suppl):S142‐S146.
Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta‐analysis. Statistics in Medicine 2001;20(4):641‐54.
Manzia TM, De Liguori Carino N, Orlando G, Toti L, De Luca L, D'Andria D, et al. Use of mycophenolate mofetil in liver transplantation: a literature review. Transplant Proceedings 2005;37(6):2616‐7.
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13.
Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after liver transplantation of a nonrenal organ . New England Journal of Medicine 2003 ; 349 ( 10 ):931‐40.
Olyaei AJ, DeMattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Current Opinion in Critical Care 2001;7:384‐9.
Perry TW, Christians U, Trotter JF, Bendrick‐Peart J. Pharmacokinetics of enteric‐coated mycophenolate sodium in stable liver transplant recipients. Clinical Transplantation 2007;21:413‐6.
Punch JD, Hayes DH, LaPorte FB, McBride V, Seely MS. Organ donation and utilization in the United States, 1996‐2005. American Journal of Transplantation 2007;7(5 pt 2):1327‐38.
Renz JF, Lightdale J, Mudge C, Bacchetti P, Watson J, Ascher NL, et al. Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients. Liver Transplantation and Surgery 1999;5(2):136‐43.
The Cochrane Collaboration. Review Manager (RevMan). Version Version 5 for Windows. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2008.
Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591‐603.
Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine 2007;27(5):746‐63.
Schmeding M, Neumann UP, Neuhaus R, Neuhaus P. Mycophenolate mofetil in liver transplantation‐is monotherapy safe?. Clinical Transplantation 2006;20(Suppl 17):S75‐S79.
Schmitz V, Laudi S, Moeckel F, Puhl G, Stockmann M, Tran ZV, et al. Chronic renal dysfunction following liver transplantation. Clinical Transplantation 2008;22(3):333‐40.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12.
Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001;357(9256):609‐10.
Toyoki Y, Renz JF, Mudge C, Ascher NL, Roberts JP, Rosenthal P. Allograft rejection in pediatric liver transplantation: comparison between cadaveric and living related donors. Pediatric Transplantation 2002;6(4):301‐7.
Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double‐blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transplantation 2001;7(5):442‐50.
Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long‐term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transplantation 2005;11(7):750‐9.
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed) 2008;336:601‐5.
